Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26

Benzinga Newsdesk www.benzinga.com Neutral 59.9%

Neg 0% Neu 59.9% Pos 0%

Truist Securities analyst Supawat Thongthip assumes Janux Therapeutics (NASDAQ:JANX) with a Buy rating and lowers Price Target of $26.